Apimeds Pharmaceuticals US (APUS) Debt Ratio (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Debt Ratio for 4 consecutive years, with 0.11 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Debt Ratio changed N/A year-over-year to 0.11; the trailing twelve-month figure through Jun 2026 stood at 0.11 (changed N/A YoY), and the FY2025 full-year result was 0.04, down 99.77% from the prior year.
• Debt Ratio improved to 0.11 in Q2 2026 per APUS's latest filing, from 0.04 in the prior quarter.
• Across five years, Debt Ratio topped out at 19.15 in Q4 2024 and bottomed at 0.04 in Q4 2025.
• Historically, Debt Ratio has averaged 4.47 across 4 years, with a median of 0.63 in 2023.
• The sharpest annual moves came in 2024 and 2025: Debt Ratio soared 2927.98% in 2024, then plunged 99.77% in 2025.
• Over 4 years, Debt Ratio stood at 0.63 in 2023, then jumped by 2927.98% to 19.15 in 2024, then tumbled by 99.77% to 0.04 in 2025, then jumped by 152.3% to 0.11 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.11, 0.04, and 2.4 for Q2 2026, Q4 2025, and Q1 2025 respectively.